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Introduction: Obstructive sleep apnea (OSA) is often connected with arterial hypertension
and it could also be a cause of secondary hypertension. Treatment of arterial hypertension
and optimal blood pressure level are important for prevention of cardiovascular complica-
tions. It is not well known how to treat patients with OSA and arterial hypertension. Also
many patients with OSA suffer from metabolic syndrome which worsen their prognosis.
Aim: The aim of our study was to assess arterial hypertension compensation in patients with
metabolic syndrome and moderate to severe OSA and to analyze used pharmacotherapy.
Materials and methods: 85 hypertensive patients (75 men) with metabolic syndrome, average
age 53.6  9.3 years, were evaluated using overnight sleep study with diagnosis of OSA,
average apnea–hypopnea index (AHI) 56.3  23. Patients underwent 24 h ambulatory blood
pressure monitoring (ABPM) and their current pharmacotherapy data were obtained. Ap-
propriate combinations of antihypertensive drugs (patients with metabolic syndrome) were
derived from ESH/ESC 2013 guidelines.
Results: Arterial hypertension was well compensated in only 11.8% of the patients. 24.7%
patients were treated according to current guidelines. Fisher's exact test with analysis of
adjusted residues has found higher rate of blood pressure subcompensation in patients
treated with triple+ combination of drugs ( p = 0.035, 51.4% vs 10%).
Conclusion: Only a small number of patients had optimal blood pressure level and were
treated according to current ESH/ESC guidelines. We have to constantly appeal to all
physicians to perform ABPM in patients with OSA.
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Obstructive sleep apnea (OSA) is classiﬁed as a sleep breathing
related disorder [1]. This disorder is affecting approximately
2–4% of adult population [2] and it represents many risks that
could inﬂuence morbidity and mortality of patients. OSA is
characterized by a presence of more than 5 apneic or hypopneic
pauses (at least 10 s in duration) per hour of sleep. Typical
symptoms are snoring with apneic pauses and an increased
daytime sleepiness as a consequence of repeated microarousals
and sleep fragmentation. Patients are often complaining about
microsleeps and falling asleep during monotone activities.
Patients also suffer from diminished concentration, impaired
memory, decrease of intellectual capacities and depression.
They feel tired during the morning, polyuria and night sweating
are present and sexual dysfunction is also more frequent [1].
During the last few decades of intensive research it was
found that the prevalence of OSA is higher in patients with
arterial hypertension (30–83%), with heart failure (12–53%),
with ischemic heart disease (30–58%) and with cerebrovascular
disorders (43–91%) [3].
Arterial hypertension is one of the most potent risk factors
for cardiovascular diseases. 50% of the patients with OSA also
have arterial hypertension and 30% of hypertensive patients
suffer from OSA [4]. In OSA patients, arterial hypertension
usually has a characteristic of so-called non-dipper type of
arterial hypertension [5,6]. In patients with resistant hyper-
tension, OSA is present in up to 83% of the patients [7]. Masked
hypertension (MH) is deﬁned as a blood pressure level that is
higher during home measurement (24 h blood pressure
monitoring (ABPM) or self monitoring) than casual blood
pressure level measured in the ofﬁce [8,9]. An arbitrary
threshold of masked hypertension has been deﬁned as blood
pressure level during the day >135/85 mmHg measured by
ABPM [9]. The prevalence of masked hypertension in general
population is estimated to be 10–25% [9–11]. Presence of
masked hypertension possibly means worst patient's progno-
sis [8]. Controversial remains the fact that mere assessment of
blood pressure during the day does not detect nocturnal
hypertension which then remains unrecognized. Mainly in
patients with OSA the prevalence of nocturnal hypertension
can be high and it can worsen prognosis of these patients. Only
sporadic papers about prevalence of masked hypertension in
patients with OSA exist [12–14].
It is not well known, how to treat patients with OSA and
arterial hypertension. Few guidelines dealing with this
problem have been published (2013 ESH/ESC Guidelines for
the management of arterial hypertension [15] and Recom-
mendation for the management of patients with obstructive
sleep apnoea and hypertension (2013)) [16], but even in these
guidelines is not stated if the pharmacotherapy of arterial
hypertension should be modiﬁed with respect to obstructive
sleep apnea. In the literature, we have found only one paper
which was evaluating medication in these patients [17]. Here
Nerbass et al. in a group of 186 patients showed that 37%
patients were treated with ACEi, 35% with beta-blocking
agents, 32% with ARB, and 21% with CCB.
Many patients with OSA also suffer from metabolic
syndrome (MS). Coughlin et al. have found up to 9.1 timeshigher risk of metabolic syndrome development in OSA
patients when compared with control group [18]. Treatment
of arterial hypertension in patients with metabolic syndrome
is well deﬁned in current guidelines. The treatment should
start with angiotensin converting enzyme inhibitors (ACEi) or
angiotensin receptor blockers (ARBs). It is also possible to use a
combination of these drugs together with calcium channel
blockers (CCBs). We chose this group of patients because
treatment of arterial hypertension is well deﬁned in this group.
The aim of our study was to assess blood pressure
compensation in these patients with MS and moderate to
severe OSA and to analyze used pharmacotherapy.
Materials and methods
Into this study were consecutively enrolled 85 patients (75
men) with arterial hypertension diagnosed according to
current guidelines [15], average age 53.6  9.3 years with
diagnosis of metabolic syndrome according to American Heart
Association [19] and with OSA (average apnea–hypopnea index
56.3  23) newly diagnosed by standard overnight polysomno-
graphy (Alice 5, Respironics, USA or Miniscreen, F+G,
Germany). Recordings were manually rescored by an experi-
enced physician with appropriate certiﬁcation issued by
national sleep medicine society. Standard deﬁnitions of apnea
(ﬂow cessation >10 s) and hypopnea (ﬂow limitation >50% and
blood oxygen saturation decrease >3%) were used. Apneas
were classiﬁed as obstructive, mixed and central according to
the presence or absence of respiratory efforts. Following
parameters of sleep apnea syndrome were further analyzed –
apnea–hypopnea index (AH), oxygen desaturation index (ODI),
average night blood oxygen saturation (SpO2), and percentage
of sleep time when SpO2 <90%.
We performed physical examination including blood
pressure measurement according to ESH/ESC 2013 [15] guide-
lines using standard sphygmomanometer which was regularly
calibrated. We have measured anthropometric parameters
such as body mass index (BMI = patients weight (kg)/patients
height (m)2), and waist, neck and hip circumference. Patients
ﬁlled Epworth sleepiness scale questionnaire. Ambulatory
blood pressure measurement was performed using Spacelabs
(Spacelabs Healthcare) device before OSA treatment was
started. Following arbitrary values were deﬁned as targets:
mean measured blood pressure (mBP) 130/80 mmHg for 24-h
interval; mBP 135/85 mmHg during daytime and mBP 120/
70 mmHg during night [20].
Patient's pharmacotherapy data were obtained and equiv-
alent doses of chosen substances were calculated using Food
and Drug Administration data.
Recommended therapeutic regimes (patients with hyper-
tension and MS) were derived from current European Society
of Hypertension/European Society of Cardiology 2013 guide-
lines [15]. As a ﬁrst line treatment authors recommended
angiotensin converting enzyme inhibitor (ACEi) or angiotensin
receptor blocker (ARB). These two groups of treatment were
combined into one group (A) because of easier results
reproducibility and because of their similar pharmacokinetic
and pharmacodynamic properties. As a second line treatment,
the guidelines recommend calcium channel blocker (CCB).
Table 2 – List of comorbidities.
Comorbidity N %
Cerebrovascular disease 7 8.2
Type 2 diabetes mellitus 22 25.9
Ischemic heart disease 9 10.6
Hyperuricemia 17 20.0
Table 3 – Results of office and 24 h ambulatory blood
pressure monitoring (ABPM).
Blood pressure (mmHg)
Ø  SD
Ofﬁce blood pressure Systolic 135.8  12.7
Diastolic 82.5  10.3
Results of ABPM
24 h Systolic 137.0  12.6
Diastolic 80.5  8.1
Daytime Systolic 139.9  13.0
Diastolic 83.3  8.9
Night Systolic 132.6  14.9
Diastolic 76.2  9.5
Table 4 – Antihypertensive treatment in the study group.
N %
ACEi 41 48.2
ARB 24 28.2
CCB 37 43.5
Diuretics 32 37.6
Beta-blocking agent 39 45.9
Centrally acting agent 19 22.4
Without therapy 11 12.9
Monotherapy 17 20.0
Double combination 18 21.2
Triple+ combination 39 45.6
Adequate combination 21 24.7
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 5 7 – e 1 6 2 e159Diuretics are according to these guidelines recommended as
antihypertensives of subsequent line treatment.
From this study were excluded patients who were exam-
ined or treated due to cause of secondary arterial hypertension
other than OSA, patients who refused to provide informed
consent, patients who refused to undergo ABPM or whose
ABPM recordings were inadequate. Other exclusion criteria
were applied as the following: congestive heart failure, atrial
ﬁbrillation, chronic obstructive pulmonary diseases of III–IV
stage according to GOLD classiﬁcation, interstitial lung disease
and malignant neoplasms.
Conduction of this study has been approved by the
appropriate Institutionary Review Board.
Data were analyzed using SPSS version 15 (SPSS Inc.,
Chicago, USA). The normality of data was tested using the
Shapiro–Wilk test. Statistical evaluation was carried out using
Student's t test, the Mann–Whitney U test at signiﬁcance level
of 0.05 and Fisher's exact test with analysis of adjusted
residues.
Results
Basic clinical parameters are presented in Table 1. Comorbid-
ities are listed in Table 2. Table 3 presents results of ofﬁce and
24 h ambulatory blood pressure monitoring.
Only 11.8% of the patients had correctly compensated
arterial hypertension (reached all target values). Masked
hypertension was present in 60% of the patients and nocturnal
hypertension in 84.7% of the patients.
Overview of arterial hypertension pharmacotherapy is
presented in Table 4. Only 24.7% of the patients were treated
according to current guidelines. Most of the patients were
treated with ACEi/ARB (76.4%), on the second place wasTable 1 – Basic clinical parameters.
Number of subjects 85 (75 male)
Age (years)
Ø  SD 53.6  9.3
Body mass index
Ø  SD 36.6  5.3
% of body fat
Ø  SD 36.5  6.0
Neck circumference (cm)
Ø  SD 45.4  3.6
Waist circumference (cm)
Ø  SD 119.8  11.2
Hip circumference (cm)
Ø  SD 117.2  0.1
Epworth sleepiness scale
Median (minimum–maximum) 10.4 (5.0–21.0)
Apnea–hypopnea index
Median (minimum–maximum) 56.3 (15.0–114.0)
Average night saturation (%)
Median (minimum–maximum) 88.9 (64.0–95.0)
Oxygen desaturation index
Median (minimum–maximum) 60.5 (19.0–118.4)
% of sleep time <90% SpO2
Median (minimum–maximum) 37.0 (2.0–99.0)
Rest heart rate (beats per minute) 74.2 (50.0–95.0)
ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin
receptor blockers; CCB, calcium channel blockers.therapy with beta-blocking agents and CCB on the third place.
Diuretics as a third agent in combination therapy were used in
only 36% of the patients (Table 5).
When we calculated the equivalent doses of antihyperten-
sives, we have found following results: ACEi – 10.9  8.2 mg of
perindopril, ARB – 70.7  30.1 mg of losartan, CCB – 6.9
 3.6 mg of amlodipine, and beta-blocking agent 117.1
 54.2 mg of metoprolol. These relatively low doses of ARB,
CCB and beta-blocking agent present evidence of general
under dosage of antihypertensives in general population.
When we analyzed whether patients with more potent
combinations also had better blood pressure compensation,
Fisher's exact test with analysis of adjusted residues has found
that in the group of incorrectly compensated patients there
was a statistically signiﬁcant increase in the use of the triple+
(three and more drugs) combination of antihypertensives
p = 0.035 (51.4% vs 10%). We have not found signiﬁcant
correlation between number of drugs and presence of
nocturnal or masked hypertension ( p = 0.145; p = 0.248).
Correlation between OSA parameters and pharmacological
groups is shown in Table 6. When comparing parameters of
Table 5 – Overview of used diuretics.
Diuretics (32 patients) N %
Hydrochlorothiazide (HCT) 16 50.0
Furosemide 7 21.8
HCT + amiloride 5 15.6
Indapamide 4 12.5
HCT, hydrochlorothiazide.
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Student's t-test, we have not found any statistically signiﬁcant
correlation between these modalities.
Discussion
We have found high rate of inadequate compensation of
arterial hypertension in patients with moderate to severe
obstructive sleep apnea with MS, only 11.8% of the patients
had correctly compensated arterial hypertension. This could
have signiﬁcant impact on patients prognosis because reduc-
tion of systolic BP >10 mmHg and of diastolic BP >5 mmHg
leads to reduction of cardiovascular risk of 22% and risk of
brain stroke of 41% [21]. Low rate of optimal blood pressure
compensation in comparison with general population as was
for example published by National Center for Health Statistics
data from 2009 to 2010 [22] where 53.3% of the patients had
optimal control of arterial hypertension could be inﬂuenced by
usage of ofﬁce blood pressure measurement. The other
possible cause could be inﬂuence of untreated OSA.
In available literature we have found one study of arterial
hypertension compensation in patients with OSA. Here Sasaki
et al. [23] showed that 47% of the patients had optimal blood
pressure level. The difference could be explained by less
selected group of patients in comparison with our patients
with arterial hypertension and MS.
The possible effect of time medication dosing on wrong
arterial hypertension compensation was excluded by using
ABPM. High prevalence of inadequate arterial hypertension
compensation is also explainable by poor compliance with
pharmacotherapy and under dosing of medicaments. We
could observe adequate mean of ACEi but under dosage in
remaining groups. But even in ACEi group, we have to say that
high standard deviation means inadequate treatment in many
patients. In general, under dosage of antihypertensives
present important problem in nowadays clinical practice
and we have to focus on this in the future research.
Masked hypertension was present in 60% of the patients in
contrast with general population where it is estimated to beTable 6 – Correlation between parameters of OSA and types of
Obstructive sleep apnea parameter ACEi/ARB 
Apnea–hypopnea index 0.687 
Oxygen desaturation index 0.788 
Average night saturation 0.760 
Epworth sleepiness scale 0.783 
Blood oxygen saturation <90% 0.965 
ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin recep10–25% [9]. In patients with OSA, usage of ABPM is recom-
mended to monitor blood pressure level and prevalence of
resistant hypertension, nocturnal blood pressure non-dipping
and to assess efﬁcacy of CPAP treatment on arterial hyperten-
sion [24].
Patients with triple+ combination showed statistically
signiﬁcant lack of arterial hypertension compensation when
compared with other types of treatment. We could hypothe-
size that this effect was just a matter of arterial hypertension
severity, where patients with more potent treatment require-
ment were more susceptible to masked hypertension
presence.
Pharmacotherapy of arterial hypertension should be led
according to current ESH/ESC guidelines. Because there are not
available guidelines for arterial hypertension pharmacothera-
py in patients with OSA, we choose the subgroup of patients
with MS in which recommended therapy is clearly deﬁned.
According to our results, only 24.7% of the patients were
adequately treated. Out of the used pharmacotherapy groups,
in the ﬁrst place were ACEi/ARBs and beta-blocking agents in
the second place. A similar treatment management was found
in a study published by Nerbass et al. [17].
Only a limited number of arterial hypertension pharmaco-
therapy studies in OSA patients exist.
One of the previous studies using clonidine has found that
this treatment could reduce the number of apneic episodes
and improve nocturnal hypoxemia [25].
One study comparing atenolol, amlodipine, enalapril,
hydrochlorothiazide and losartan has found similar effect of
this pharmacotherapy on average daytime blood pressure [26].
In the same study atenolol had the most pronounced effect on
nocturnal hypertension.
In 2010 Zou et al. published results of double blinded study
of doxazosin vs enalapril therapy in patients with arterial
hypertension [27]. There was found worst arterial hyperten-
sion compensation in patients taking doxazosin.
According to some studies [28,29], these patients could
beneﬁt from beta-blocking agents. It was found that in patients
with OSA the activity of sympathetic nervous system is
elevated [30]. Using beta-blocking agents, we could block this
undesired effect. Heitmann et al. [28] have compared nebivolol
and valsartan therapy in patients with OSA and have not
found any signiﬁcant difference in primary goal – arterial
hypertension compensation. Another question is, which agent
to use, more lipo- or hydrophilic. Maybe in the future there will
be studies performed that will ﬁnd answers to these questions.
The other discussed agent is spironolactone. It has been
found that treatment of OSA patients with spironolactone
leads to 50% reduction in OSA severity [31]. Here Gaddam et al. antihypertensives.
CCB Diuretics Beta-blockers
0.092 0.662 0.293
0.139 0.317 0.199
0.452 0.079 0.448
0.431 0.702 0.926
0.515 0.095 0.511
tor blockers; CCB, calcium channel blockers.
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orofacial area and thus it could decrease severity of OSA. This
study also found a positive effect of spironolactone on blood
pressure compensation in these patients. In our study none of
the patients was treated with this drug.
Nerbass et al. showed that CCB could have negative impact
on sleep duration in patients with OSA [17]. We have not found
any signiﬁcant correlation between medication and parame-
ters of OSA.
In the review published in 2011, Ziegler et al. [29]
recommend the use of beta-blocking agents, ACEi or ARB
in patients with OSA and arterial hypertension. If patient's
BP is not compensated using this treatment, they recom-
mend adding spironolactone into the therapy and using
evening dosage to suppress the effect of nocturnal hyper-
tension.
Limitation of this study is usage of polygraphy without
electroencephalography (EEG) in some patients together with
full polysomnography, which leaves some space for possible
inaccuracy in obstructive sleep apnea evaluation. But this
study is not focused on sleep apnea severity. Here we are using
sleep study to identify patients with obstructive sleep apnea
and to this purpose polysomnography without EEG has
sufﬁcient sensitivity and speciﬁcity. The other limitation is
a relatively small sample size. In the future, we plan to perform
a larger study with sufﬁcient sample size to shed more light on
this issue.
Conclusion
We have found a very high rate of inadequate compensation of
arterial hypertension in patients with moderate to severe
obstructive sleep apnea with MS. Only a small number of
patients with OSA and MS were treated according to current
ESH/ESC guidelines. From these results it is evident that
optimization of antihypertensive treatment can be much
better and we have to constantly appeal to physicians to
perform 24 h ambulatory blood pressure monitoring in order
to achieve better diagnosis and treatment of masked and
nocturnal hypertension.
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